Importance of Patient-Reported Outcomes in the GRIFFIN Study

Video

Rebecca Silbermann, MD, MMS, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study and the importance of individualizing treatment for patients with multiple myeloma.

Rebecca Silbermann, MD, MMS, associate professor of medicine at the Division of Hematology/Medical Oncology at Oregon Health & Science University, discusses the relevance of patient-reported outcomes from the phase 2 GRIFFIN study (NCT02874742) and the importance of individualizing treatment for patients with multiple myeloma.

Recently, Silbermann reported on findings from the phase 2 GRIFFIN study which assessed the addition of daratumumab (Darzalex) to bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (RVd) induction/consolidation therapy, along with lenalidomide maintenance in patients with transplant-eligible, newly diagnosed multiple myeloma.

Findings showed that the combination led to a promising health-related quality-of-life benefit among this patient population, These results add to the substantial evidence regarding the benefits of the addition of daratumumab for patients with transplant-eligible multiple myeloma.

Silbermann notes how recognizing these results from the GRIFFIN study will continue to improve patient outcomes moving forward.

Transcription:

0:08 | I think it is important for patients with myeloma to realize that they often will begin to feel better as they're being treated. Many patients presumed that television and movie perceptions of how cancer treatments look will be applicable to them. And that is not always the case for myeloma patients.

0:28 | I think that the use of these patient reported outcomes is going to be increasingly important in clinical trials. Patients really want to know what to expect when they're being treated. And I think it is important for the physicians and the other members of the treatment team to understand how the patients think that they are doing.

0:44 | I think we are recognizing that maintenance therapy is not always easy for patients and that while patients are generally feeling better, I think that we are realizing that patients are very different from each other, and that we have to keep assessing each individual person.

Recent Videos
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Sham Mailankody, MBBS, an expert on multiple myeloma
Related Content